Abstract:
Multiple sclerosis (MS) is an incurable autoimmune disease and is currently treated by systemic immunosuppressants with off-target side effects. Although aberrant myeloid function is often observed in MS plaques in the central nervous system (CNS), the role of myeloid cells in therapeutic intervention is currently overlooked. Here, we developed a myeloid cell-based strategy to reduce the disease burden in experimental autoimmune encephalomyelitis (EAE), a mouse model of progressive MS. We developed monocyte-adhered microparticles ("backpacks") for activating myeloid cell phenotype to an anti-inflammatory state through localized interleukin-4 and dexamethasone signals. We demonstrate that backpack-laden monocytes infiltrated into the inflamed CNS and modulated both the local and systemic immune responses. Within the CNS, backpack-carrying monocytes regulated both the infiltrating and tissue-resident myeloid cell compartments in the spinal cord for functions related to antigen presentation and reactive species production. Treatment with backpack-monocytes also decreased the level of systemic pro-inflammatory cytokines. Additionally, backpack-laden monocytes induced modulatory effects on T(H)1 and T(H)17 populations in the spinal cord and blood, demonstrating cross talk between the myeloid and lymphoid arms of disease. Backpack-carrying monocytes conferred therapeutic benefit in EAE mice, as quantified by improved motor function. The use of backpack-laden monocytes offers an antigen-free, biomaterial-based approach to precisely tune cell phenotype in vivo, demonstrating the utility of myeloid cells as a therapeutic modality and target.
Notes:
Kapate, Neha Dunne, Michael Kumbhojkar, Ninad Prakash, Supriya Wang, Lily Li-Wen Graveline, Amanda Park, Kyung Soo Chandran Suja, Vineeth Goyal, Juhee Clegg, John R Mitragotri, Samir eng Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. 2023/04/19 Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2221535120. doi: 10.1073/pnas.2221535120. Epub 2023 Apr 19.
Website
